Cell therapy for emphysema in chronic obstructive pulmonary disease
Part of Lungs & breathing clinical trials.
This phase 3 trial tests a new cell-based treatment (REGEND001) for people with moderate to severe COPD, especially those with emphysema. The treatment aims to repair damaged lung tissue, potentially improving breathing and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Between 40 and 75 years old
- Have COPD with emphysema (damaged air sacs in the lungs), confirmed by a special CT scan
- Have moderate to severe COPD based on breathing tests (FEV1 after using a bronchodilator)
- Be generally stable - no severe flare-ups needing hospitalization in the last 2 months, and no more than one in the past year
- No history of cancer (current or past)
- Be willing to avoid taking blood-thinning medications for at least a week before the procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug for people with moderate to severe COPD, especially those with chronic bronchitis. It aims to see how the drug affects certain markers in your body and whether it helps with your COPD symptoms.
This trial tests whether a special stem cell treatment can help people with moderate to severe COPD when regular medicines are not working well. The treatment may reduce breathing problems and improve quality of life.
This trial is testing a new type of cell therapy called REGEND007 for people with COPD. It looks at whether the treatment can help improve how far you can walk and your overall breathing.
This trial tests a new cell-based therapy for people with IPF, a lung condition that causes scarring and breathing problems. The goal is to see if the treatment can help slow the disease and improve breathing ability.
This trial tests a cell-based treatment placed into the lung using an airway valve, to help people with severe emphysema breathe easier. You may be eligible if your emphysema is uneven in the lungs and testing suggests your “collateral ventilation” is low, meaning the treatment area may benefit more from blocking airflow.
This study tests a new treatment made from small mobile stem cells, given by inhalation, for people with moderate to severe COPD caused by smoking or pollution. It aims to see if the treatment is safe and helps improve lung function.
Hear when a new COPD (Chronic Obstructive Pulmonary Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.